In a significant step forward, the Ministry of Ayush has paved the way for strengthening the quality of Ayurvedic and other Indian Traditional Medicine products globally and also enhancing their export potential, especially to the USA Market. This has been achieved by signing of a Memorandum of Understanding (MoU) between the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) and American Herbal Pharmacopoeia, USA on 13thSeptember, 2021.
The MoU was signed virtually and the Ministry of Ayush has entered this MOU with the specific purpose of strengthening, promotion, and development of standards in the field of Ayurveda and other Indian Traditional systems of medicine between the two countries on the basis of equality and mutual benefit.
This collaboration of efforts will go a long way in enhancing the export potential of the ASU&H (Ayurveda, Siddha, Unani and Homeopathy) drugs. Under this MOU, there will be the constitution of a Joint Committee to develop the action plan along with timelines for the development of Monographs and other activities for cooperation in the field of Traditional Medicine.
The Ministry feels that this MOU will develop the confidence of the global community about the safety of ASU&H drugs. One of the major outcomes of this partnership will be that both PCIM&H and AHP, USA would be working to identify various challenges faced by theherbal market of Ayurveda products/drugs in the USA. This will lead to adoption of Ayurveda standards developed out of this cooperation by the manufacturers of herbal drugs in the USA. This can be termed as a major move and will eventually foster the adoption of Ayurveda standards developed out of this cooperation for the market authorization of ASU&H products/drugs in the USA.
Development of Monographs of Ayurveda & other Indian Traditional Medicine products and herbal products, exchange of technical data for the development of Monographs with due acknowledgement between the parties, training and capacity building, exchange of Herbarium specimens and Botanical Reference Samples and phytochemical reference standards are also the part of MoU. There is an understanding in development of a Digital database on Ayurveda & other Indian Traditional Medicine products/drugs and herbal products and identifying further areas of co-operation for the promotion of quality standards of drugs/products used in Ayurveda & other Indian Traditional Medicine.
This MoU between India and USA is a timely step to add further momentum to the ongoing initiatives of the Ministry of Ayush to strengthen the quality of Ayurveda and other Indian Traditional Medicine products both inland and globally. Ayurveda and other AYUSH medicines have much to contribute in dealing with lifestyle disorders which are the major killers of this century.
Further, the role of ASU&H drugs in promoting the immunity of the body to fight against the prevalent infections is evidence based and worth praising. India enjoys the distinction of having the largest network of traditional health care systems which are widely accepted owing to its wide accessibility, affordability, safety and trust of people. It is the mandate of the Ministry of Ayush to work for promotion and propagation of these systems at international level for its global acceptance.
Through this MoU both the collaborators would strive to recognize the role of standards ensuring the quality and safety of Ayurveda and other Indian Traditional Medicine products. Will ensure an increase in awareness and understanding of the quality of traditional herbal medicines and their products.
Read More► Centre Enhances Financial Support to Open Ayush Colleges From Rs 9 Crore to Rs 70 Crore
आयुष मंत्रालय ने आयुर्वेदिक और अन्य भारतीय पारंपरिक दवाओं की गुणवत्ता बढ़ाने का रास्ता तैयार कर दिया है। इससे दुनिया में इन दवाओं की उपस्थिति बढ़ेगी और निर्यात क्षमता में भी वृद्धि होगी। इसमें अमेरिका के बाजार का विशेष स्थान है। भारतीय चिकित्सा एवं होम्योपैथी भेषजसंहिता आयोग (पीसीआईएम-एंड-एच) ने अमेरिकन हर्बल फॉर्माकोपिया (एएचपी) के साथ 13 सितंबर, 2021 को एक समझौता-ज्ञापन पर हस्ताक्षर करके यह महत्त्वपूर्ण काम अंजाम दिया है।
इस समझौता-ज्ञापन पर वर्चुअल माध्यम से हस्ताक्षर किये गये। समझौता करने के सम्बंध में आयुष मंत्रालय का उद्देश्य है कि दोनों देशों के बीच बराबरी तथा आपसी लाभ के आधार पर आयुर्वेद और अन्य भारतीय पारंपरिक औषधि प्रणालियों को प्रोत्साहित किया जाये और उनके मानकीकरण का विकास किया जाये।
इस सहयोग से आयुर्वेद, सिद्ध, यूनानी और होम्योपैथी दवाओं की निर्यात क्षमता को बढ़ाने के दूरगामी प्रयास होंगे। समझौते के तहत एक संयुक्त समिति का गठन किया जायेगा, ताकि पारंपरिक औषधि के क्षेत्र में सहयोग के हवाले से मोनोग्राफ के विकास तथा अन्य गतिविधियों के लिये समय-सीमा के साथ एक कार्य योजना भी विकसित की जाये।
आयुष मंत्रालय को विश्वास है कि इस समझौते से आयुर्वेद, सिद्ध, यूनानी और होम्योपैथी दवाओं के बारे में विश्व समुदाय में भरोसा पैदा होगा। इस साझेदारी का एक प्रमुख नतीजा यह होगा कि पीसीआईएम-एंड-एच और एएचपी, अमेरिका में आयुर्वेद उत्पादों/दवाओं के बाजार के सामने आने वाली विभिन्न चुनौतियों की मिलकर पहचान करेंगे। इस कदम से सहयोग के तहत विकसित होने वाले आयुर्वेद मानकों को अमेरिका के हर्बल दवाओं के निर्माता अपना लेंगे। इसे एक बड़ा कदम कहा जा सकता है और फलस्वरूप सहयोग के तहत विकसित आयुर्वेद मानकों को अपनाये जाने से अमेरिकी बाजार में आयुर्वेद, सिद्ध, यूनानी और होम्योपैथी दवाओं को बेचने का रास्ता खुल जायेगा।
आयुर्वेद और अन्य भारतीय पारंपरिक औषधियों और जड़ी-बूटियों से बने उत्पादों के लिये मोनोग्राफ का विकास, पक्षों के बीच मोनोग्राफ के विकास के लिये तकनीकी आंकड़ों का आदान-प्रदान, प्रशिक्षण और क्षमता निर्माण, जड़ी-बूटियों के नमूने, वनस्पतियों के नमूने तथा पौधों के रासायनिक मानकों को भी समझौते का अंग बनाया गया है। दोनों पक्षों के बीच यह समझ भी बनी है कि आयुर्वेद और अन्य भारतीय पारंपरिक दवा उत्पादों तथा जड़ी-बूटियों के उत्पादों के लिये एक डिजिटल डेटाबेस बनाया जाये। इसके तहत आयुर्वेद और अन्य भारतीय पारंपरिक दवाओं के इस्तेमाल के बारे में गुणवत्ता मानकों को प्रोत्साहित करने के लिये सहयोग के अन्य उपायों की पहचान की जायेगी।
भारत और अमेरिका के बीच यह समझौता ऐसे समय में हुआ है, जब आयुष मंत्रालय भारत और विदेश में आयुर्वेद तथा अन्य भारतीय पारंपरिक औषधीय उत्पादों की गुणवत्ता बेहतर बनाने के लिये कई कदम उठा रहा है। आयुर्वेद और अन्य आयुष दवाओं ने गलत जीवन-शैली से पैदा होने वाली बीमारियों से निपटने में बहुत योगदान किया है। इन बीमारियों से इस सदी में तमाम लोग मृत्यु को प्राप्त हुये हैं।
इसके अलावा, संक्रमण के खिलाफ लड़ने को शरीर की रोग विरोधी क्षमता को बढ़ाने में भी आयुर्वेद, सिद्ध, यूनानी और होम्योपैथी की अहम भूमिका है, जिसके प्रमाण सबके सामने हैं। यह अत्यंत प्रसंशनीय है। भारत को पारंपरिक स्वास्थ्य सुविधा प्रणाली का वरदान मिला है। यह प्रणालियां बड़े पैमाने पर मान्य हैं, क्योंकि ये आसानी से उपलब्ध हैं, सस्ती, सुरक्षित हैं और लोगों को उन पर भरोसा है। यह आयुष मंत्रालय के अधिकार-क्षेत्र में है कि वह इन औषधियों को दुनिया भर में मान्य करने के लिये वह अंतर्राष्ट्रीय स्तर पर इन प्रणालियों का प्रचार-प्रसार करे।
इस समझौता-ज्ञापन से दोनों पक्ष आयुर्वेद और अन्य भारतीय पारंपरिक औषधीय उत्पादों की गुणवत्ता तथा सुरक्षा सुनिश्चित करने के लिये मानकों की भूमिका को मान्यता प्रदान करेंगे। इससे पारंपरिक/हर्बल दवाओं और उनके उत्पादों की गुणवत्ता के प्रति समझ तथा जागरूकता बढ़ेगी।
यह भी पढ़े► केंद्र पूर्वोत्तर में नए आयुष कॉलेज खोलने में मदद को तैयार: सर्बानंद सोनोवाल
New Delhi, Sep 7 (IANS) Nearly nine out of 10 doctors and nutritionists believe that the average daily Indian diet fulfills only 70 per cent or even lower nutritional needs of a person, according to a survey released on Tuesday.
The findings are based on a nationwide survey of 220 healthcare practitioners (doctors and nutritionists) by multivitamin supplement brand Supradyn.
The survey brought to light an alarming gap in meeting the body's 100 per cent nutrition requirements across all zones in India.
As many as 90 per cent doctors and nutritionists agreed to at least a 30 per cent nutrition gap in average daily diet even among states that predominantly consume non-vegetarian foods.
Further, the survey showed that vitamin B12 and D3 are the top two vitamins lacking in an average daily diet across the country, followed by zinc, iron, calcium, folic acid, and vitamin C.
A whopping 73 per cent doctors and nutritionists believe that this inadequacy can be overcome with a daily dose of multivitamin-multimineral supplements.
"The doctor-led nutrition survey has identified a surprisingly large nutrition gap in our daily diets, highlighting a grave insufficiency of micronutrients," said Sandeep Verma, Country Head, India, Bayer Consumer Health Division, in a statement.
"This survey has brought to life a surprising truth: an average daily diet cannot always meet 100 per cent of your body's nutrition requirement. Including a daily multivitamin-multimineral supplement can help bridge the nutrition gap and provide your body with optimum energy and immunity levels," added Dr Jenam P. Mehta, Consultant Physician and Chest Specialist, Member of European Respiratory Society.
With Covid-19 pandemic having reset priorities, health and wellness have risen to the top of minds. Hence, meeting daily requirements of nutrients should be looked at as a growing necessity, not just an added advantage, the survey suggested.
Pune, Aug 17 (IANS) The world's largest vaccine maker Serum Institute of India has bought 50 per cent stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry at an undisclosed amount to expand its presence in pharmaceutical packaging segment.SCHOTT Kaisha is a joint venture between Indian partners and Germany's specialty glass company SCHOTT AG. It is a leading Indian manufacturer of pharma packaging products such as vials, syringes, ampoules and cartridges used to package life-saving medications.The acquisition will also help Serum to secure its supply of high-quality pharma packaging amid rising global demand.Adar Poonawalla, CEO, Serum Institute of India, said: "Even the best medication can't reach the patient without the right packaging. Securing this supply chain is of strategic importance. SCHOTT is the perfect partner for us to do this because of their expertise and global network. As a longtime customer, we use their vials, ampoules and syringes to store our vaccines including COVISHIELD. Working closer together is in the best interest of global health."SCHOTT is looking forward to the cooperation with the new partner. Frank Heinricht, CEO SCHOTT said: "As India has steadily established its position as a global pharmaceutical hub, we are delighted to strengthen our footprint within the Indian pharma supply chain. We are looking forward to strong impulses from this partnership. It is an excellent example of shifting towards new cooperation models, with greater synergies between pharma manufacturing and packaging production."The joint venture will definitely continue to supply its customers in India and abroad as a reliable partner, said Eric L'Heureux, the new Managing Director and former longstanding Head of Operations."We have significantly increased our production capacity in India. Over the last three years we have invested roughly Rs 600 crore to set up two new plants in Umarsadi, Gujarat and Baddi, Himachal Pradesh, and to secure uninterrupted supply in our existing facilities during the pandemic."As per the fresh joint venture agreement, both SCHOTT and Serum have committed to invest further in expanding its facilities in the country. Concrete plans in this regard will be announced as the partnership evolves.Working together in the joint venture opens a new chapter in the successful partnership of Serum and SCHOTT. The companies have had a strong business relationship - and both have been playing a crucial role during the pandemic.From the onset of the COVID-19 outbreak, Serum rose to the challenge of developing and/or manufacturing life-saving vaccines, such as COVISHIELD and COVOVAX. To this day, the company has filled and delivered hundreds of millions of doses to India and the world.On the packaging end, SCHOTT has already exceeded its target to deliver vials for more than 2 billion vaccine doses through 2021. The company is providing glass vials globally to key vaccine manufacturers. The fact that SCHOTT has an integrated value chain, covering also the glass tubing the packaging is made of, further helped to secure the supply chain.--IANSsn/skp/
New Delhi, Aug 17 (IANS) Indian researchers have developed a non-invasive, easy to administer, cost-effective and patient compliant potential therapeutic strategy against Visceral Leishmaniasis, a neglected tropical disease."The strategy based on nano-carrier-based oral drugs coated with Vitamin B12 enhanced oral bioavailability and efficacy of the therapy by more than 90 per cent," a release from the Department of Science & Technology (DST) said on Monday.Visceral Leishmaniasis (VL) is a complex infectious disease transmitted by the bite of female Phlebotomies and flies. It is a neglected tropical disease that affects millions annually, making it the second most common parasitic killer after malaria.The conventional treatment therapy of VL mainly involves painful intravenous administration, which imposes many treatment complications, including prolonged hospitalisation, high cost, and high risk of infection. "Oral drug delivery brings forth massive advantages that can help overcome these barriers. But with oral routes, there are other challenges as more than 90 per cent of orally administered therapeutic drugs have less than 2 per cent bioavailability and potentially high hepatic and renal toxic side-effects," the release said.A team led by Shyam Lal from the Institute of Nano-Science and Technology (INST), an autonomous institute of the Department of Science and Technology, has developed a smart and intelligent nano-carrier utilising the natural intrinsic Vitamin B12 pathway present in human body that can mitigate stability challenges and drug-associated toxicity. The team has disguised the toxic but highly efficient drug of the disease within a biocompatible lipid nano-carrier, shielding it from degradation in the hostile gastric environment, thus overcoming the gastrointestinal enzymatic barriers endured by any foreign synthetic drug molecule."This minimied its side effects, while the natural intrinsic Vitamin B12 pathway enhanced the oral bioavailability and anti-Leishmanial therapeutic efficacy by more than 90 per cent, as shown in the associated animal studies," the release said.The INST team critically evaluated the efficacy and properties of Vitamin B12 (VB12) coated solid lipid nano-particles and their subsequent potential ramification in evading cytotoxicity and escalating stability.--IANSniv/arm
New Delhi, Aug 16 (IANS) As the Indian startup ecosystem witnesses a never-seen-before capital infusion across the spectrum, it is a golden opportunity for the health-tech startups to begin serving the nation at a large scale and help millions get right diagnosis and better treatment in the digital era, seasoned doctor-entrepreneur-investor Ritesh Malik said on Monday.Malik, who is one of the leading Covid warriors with a pledge to help around 10 lakh people get vaccinated via his Radix Healthcare facility in Delhi, emphasised that while the healthcare sector deserves more funds from the government, the current boom in the startup industry can help entrepreneurs chart out a new journey to overhaul the massive healthcare ecosystem slowly but steadily."This is a golden opportunity to serve a nation. The biggest question is how we are going to bring proper healthcare to small-town India and millions of villagers in these Covid times. To begin with, diagnostics and pharmacy startups can leverage AI/ML technologies to reach the hinterlands," Malik told IANS.He admitted that despite heavy rules and regulations and legal challenges, Indian entrepreneurs can take up the challenge to transform the fragmented healthcare sector. "Now over 300 AI companies are working on medical imaging. The new-age technology can surely transform the Indian healthtech sector. The government should also prioritise to allocate more funds to the sector so that the task becomes easy," he stressed. The budget 2021 increased the spending on healthcare by 137 per cent, in line with the GDP National Health Policy 2017 target of increasing heath spending to 2.5 per cent by 2025.India will spend Rs 2.23 lakh crore on healthcare. An amount of Rs 35,000 crore will be spent on Covid-19 vaccines as part of the Rs 2.23 lakh crore spending.In 2016, Malik started a co-working platform called Innov8 which was later acquired by Softbank-backed Oyo in 2019. Backed by Y-Combinator, innov8 is currently one of the leading Indian co-working companies.According to Malik who has invested in nearly 80 startups/companies to date, the next big revolution should come from the healthcare space in the country."India has moved beyond being a BPO or a mega customer base for the world. We are creating world-class products. We will be a huge digital democracy by 2050 and the largest software producer of the world. The healthcare startups need to jump on the bandwagon now so that millions can receive top-class diagnosis and treatment in the near future," Malik emphasised.--IANSna/